Subsequent Events	12 Months Ended
Dec. 31, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS In accordance with ASC Topic 855, Subsequent Events, which establishes general standards of accounting for and disclosure of events that occur after the consolidated balance sheet date, the Company has evaluated all events or transactions that occurred after the consolidated balance sheet date. On January 22, 2026 the Company entered into an amendment to the Investment Management Trust Agreement, with Continental Stock Transfer & Trust Company (the “Trust Amendment III”). Pursuant to the Trust Amendment III, the Company has the right to extend the time for KVAC to complete its business combination (the “Business Combination Period”) under the Trust Agreement III for a period of seven months from January 27, 2026 to July, 2026, by depositing into the Trust Account $120,000 for all remaining public shares (the “Extension Payment”) for each three-month extension. On January 22, 2026, in connection with the stockholders’ vote at the Annual Meeting, 3,781,900 shares were tendered for redemption. On January 26, 2026 the Company issued an unsecured promissory note in an amount of $120,000 to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business combination until April 27, 2026. On February 26, 2026, the Company entered into a binding letter of intent (“LOI”) with Medera and Novoheart Group Limited, a British Virgin Islands company and wholly owned subsidiary of Medera (“NVH”). The LOI replaces the prior Merger Agreement dated September 3, 2024, which was terminated concurrently with execution of the LOI pursuant to a mutual release agreement entered into by the parties. Under the LOI, Parent and NVH have agreed to use their best efforts to negotiate and execute a replacement merger agreement (“Replacement Merger Agreement”) no later than April 10, 2026. In connection with the execution of the LOI, the parties also executed a standard termination and mutual release agreement relating to the current Merger Agreement between the Company and Medera.

Subsequent Events

12 Months Ended

Dec. 31, 2025

NOTE 9 – SUBSEQUENT EVENTS

In accordance with ASC Topic 855, Subsequent Events, which establishes general standards of accounting for and disclosure of events that occur after the consolidated balance sheet date, the Company has evaluated all events or transactions that occurred after the consolidated balance sheet date.

On January 22, 2026 the Company entered into an amendment to the Investment Management Trust Agreement, with Continental Stock Transfer & Trust Company (the “Trust Amendment III”). Pursuant to the Trust Amendment III, the Company has the right to extend the time for KVAC to complete its business combination (the “Business Combination Period”) under the Trust Agreement III for a period of seven months from January 27, 2026 to July, 2026, by depositing into the Trust Account $120,000 for all remaining public shares (the “Extension Payment”) for each three-month extension.

On January 22, 2026, in connection with the stockholders’ vote at the Annual Meeting, 3,781,900 shares were tendered for redemption.

On January 26, 2026 the Company issued an unsecured promissory note in an amount of $120,000 to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a business combination until April 27, 2026.

On February 26, 2026, the Company entered into a binding letter of intent (“LOI”) with Medera and Novoheart Group Limited, a British Virgin Islands company and wholly owned subsidiary of Medera (“NVH”). The LOI replaces the prior Merger Agreement dated September 3, 2024, which was terminated concurrently with execution of the LOI pursuant to a mutual release agreement entered into by the parties. Under the LOI, Parent and NVH have agreed to use their best efforts to negotiate and execute a replacement merger agreement (“Replacement Merger Agreement”) no later than April 10, 2026. In connection with the execution of the LOI, the parties also executed a standard termination and mutual release agreement relating to the current Merger Agreement between the Company and Medera.